212 related articles for article (PubMed ID: 31023248)
1. Physician requests by patients with malignant pleural mesothelioma in Japan.
Nagamatsu Y; Oze I; Aoe K; Hotta K; Kato K; Nakagawa J; Hara K; Kishimoto T; Fujimoto N
BMC Cancer; 2019 Apr; 19(1):383. PubMed ID: 31023248
[TBL] [Abstract][Full Text] [Related]
2. Upcoming epidemic of asbestos-related malignant pleural mesothelioma in Taiwan: A prediction of incidence in the next 30 years.
Lin RT; Chang YY; Wang JD; Lee LJ
J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):463-470. PubMed ID: 30072200
[TBL] [Abstract][Full Text] [Related]
3. Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study.
Nagamatsu Y; Oze I; Aoe K; Hotta K; Kato K; Nakagawa J; Hara K; Kishimoto T; Fujimoto N
BMC Cancer; 2018 Mar; 18(1):350. PubMed ID: 29587685
[TBL] [Abstract][Full Text] [Related]
4. Pleural mesothelioma and lung cancer: the role of asbestos exposure and genetic variants in selected iron metabolism and inflammation genes.
Celsi F; Crovella S; Moura RR; Schneider M; Vita F; Finotto L; Zabucchi G; Zacchi P; Borelli V
J Toxicol Environ Health A; 2019; 82(20):1088-1102. PubMed ID: 31755376
[TBL] [Abstract][Full Text] [Related]
5. Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009.
Jennings CJ; Walsh PM; Deady S; Harvey BJ; Thomas W
Cancer Epidemiol; 2014 Feb; 38(1):35-41. PubMed ID: 24394956
[TBL] [Abstract][Full Text] [Related]
6. Increased Standardised Incidence Ratio of Malignant Pleural Mesothelioma in Taiwanese Asbestos Workers: A 29-Year Retrospective Cohort Study.
Lin CK; Chang YY; Wang JD; Lee LJ
Biomed Res Int; 2015; 2015():678598. PubMed ID: 26290869
[TBL] [Abstract][Full Text] [Related]
7. Gene-asbestos interaction in malignant pleural mesothelioma susceptibility.
Tunesi S; Ferrante D; Mirabelli D; Andorno S; Betti M; Fiorito G; Guarrera S; Casalone E; Neri M; Ugolini D; Bonassi S; Matullo G; Dianzani I; Magnani C
Carcinogenesis; 2015 Oct; 36(10):1129-35. PubMed ID: 26139392
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of pleural mesothelioma in a population with non-occupational asbestos exposure.
Metintas M; Metintas S; Ak G; Erginel S; Alatas F; Kurt E; Ucgun I; Yildirim H
Respirology; 2008 Jan; 13(1):117-21. PubMed ID: 18197921
[TBL] [Abstract][Full Text] [Related]
9. Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982-2009.
Soeberg MJ; Leigh J; Driscoll T; Armstrong B; Young JM; van Zandwijk N
Occup Environ Med; 2016 Mar; 73(3):187-94. PubMed ID: 26800709
[TBL] [Abstract][Full Text] [Related]
10. Clinical and prognostic features of erionite-induced malignant mesothelioma.
Demirer E; Ghattas CF; Radwan MO; Elamin EM
Yonsei Med J; 2015 Mar; 56(2):311-23. PubMed ID: 25683976
[TBL] [Abstract][Full Text] [Related]
11. [Clinical and pathological profile of the pleural malignant mesothelioma: A retrospective study about 30 cases].
Mlika M; Lamzirbi O; Limam M; Mejri N; Ben Saad S; Chaouch N; Ben Miled K; Marghli A; Mezni F
Rev Pneumol Clin; 2018 Dec; 74(6):427-435. PubMed ID: 30293912
[TBL] [Abstract][Full Text] [Related]
12. Iron signature in asbestos-induced malignant pleural mesothelioma: A population-based autopsy study.
Crovella S; Bianco AM; Vuch J; Zupin L; Moura RR; Trevisan E; Schneider M; Brollo A; Nicastro EM; Cosenzi A; Zabucchi G; Borelli V
J Toxicol Environ Health A; 2016; 79(3):129-41. PubMed ID: 26818092
[TBL] [Abstract][Full Text] [Related]
13. Managing malignant pleural mesothelioma: experience and perceptions of health care professionals caring for people with mesothelioma.
Warby A; Dhillon HM; Kao S; Vardy JL
Support Care Cancer; 2019 Sep; 27(9):3509-3519. PubMed ID: 30684047
[TBL] [Abstract][Full Text] [Related]
14. The minimum standard of care for managing malignant pleural mesothelioma in developing nations within the Asia-Pacific Region.
Ke H; Kao S; Lee K; Takahashi K; Goh HP; Linton A
Asia Pac J Clin Oncol; 2022 Jun; 18(3):177-190. PubMed ID: 34161674
[TBL] [Abstract][Full Text] [Related]
15. Malignant and non-malignant asbestos-related pleural and lung disease: 10-year follow-up study.
Cvitanović S; Znaor L; Konsa T; Ivancević Z; Perić I; Erceg M; Vujović M; Vuković J; Beg-Zec Z
Croat Med J; 2003 Oct; 44(5):618-25. PubMed ID: 14515425
[TBL] [Abstract][Full Text] [Related]
16. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
[TBL] [Abstract][Full Text] [Related]
17. Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles.
Andujar P; Lacourt A; Brochard P; Pairon JC; Jaurand MC; Jean D
J Toxicol Environ Health B Crit Rev; 2016; 19(5-6):151-172. PubMed ID: 27705546
[TBL] [Abstract][Full Text] [Related]
18. [Malignant pleural mesothelioma in patients hospitalised at the Clinical Hospital Centre Rijeka between 1989 and 2008].
Kricka O; Matanić Lender D; Barković I; Flego V; Kupanovac Z; Bulat Kardum L
Arh Hig Rada Toksikol; 2009 Nov; 60 Suppl():41-3. PubMed ID: 20853777
[TBL] [Abstract][Full Text] [Related]
19. Past trends and future prediction of mesothelioma incidence in an industrialized area of Italy, the Veneto Region.
Girardi P; Bressan V; Merler E
Cancer Epidemiol; 2014 Oct; 38(5):496-503. PubMed ID: 25200195
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients.
Kishimoto T; Fujimoto N; Ebara T; Omori T; Oguri T; Niimi A; Yokoyama T; Kato M; Usami I; Nishio M; Yoshikawa K; Tokuyama T; Tamura M; Yokoyama Y; Tsuboi K; Matsuo Y; Xu J; Takahashi S; Abdelgied M; Alexander WT; Alexander DB; Tsuda H
BMC Cancer; 2019 Dec; 19(1):1204. PubMed ID: 31823764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
